PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

Table 2 Patients needed for different effect sizes

Proportion of GC-free remission		Placebo group
Proportion of GC-free remission		0.5	0.45	0.4	0.35	0.3	0.25	0.2
MTX group	0.8	90	70	56	44	38	32	26
	0.75	132	96	72	56	46	38	32
	0.7	206	136	98	74	58	46	38
	0.65	366	212	140	98	74	56	44
	0.6	816	372	214	140	98	72	56
	0.55	3210	824	372	212	136	96	70
	0.5		3210	816	366	206	132	90

ISSN: 1745-6215